Syndax to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 9, 2022
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Syndax Pharmaceuticals (SNDX) will release its first quarter 2022 financial results on May 9, 2022, after U.S. market close. A conference call and audio webcast will follow at 4:30 p.m. ET to discuss the results and business updates. Interested parties can access the webcast on the company's website. Syndax's pipeline includes promising cancer therapies such as SNDX-5613, a Menin–MLL inhibitor, axatilimab, a CSF-1 receptor blocker, and entinostat, a class I HDAC inhibitor.
Positive
- Upcoming Q1 2022 financial results expected to provide insights into company performance.
- Innovative pipeline including SNDX-5613, axatilimab, and entinostat.
Negative
- None.
Details
News Market Reaction – SNDX
The recorded move for SNDX in the trading session of this news was +2.50%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., May 2, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will release its first quarter 2022 financial results on Monday, May 9, after the close of the U.S. financial markets.
In connection with the earnings release, Syndax's management team will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, May 9, to discuss the Company's financial results and provide a general business update.
The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website at www.syndax.com. Alternatively, the conference call may be accessed through the following:
Conference ID: 1394554
Domestic Dial-in Number: (855) 251-6663
International Dial-in Number: (281) 542-4259
Live webcast: https://edge.media-server.com/mmc/p/49kx4w4n
For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website, www.syndax.com.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.
Syndax Contacts
Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902
Media Contact
Benjamin Kolinski
benjamin.kolinski@gcihealth.com
Tel 862.368.4464
SNDX-G
View original content:https://www.prnewswire.com/news-releases/syndax-to-announce-first-quarter-2022-financial-results-and-host-conference-call-and-webcast-on-may-9-2022-301536956.html
SOURCE Syndax Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.